Audit: QRS - Epitalon for Health & Longevity
Audit conducted on 05/08/2026 14:37 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 81 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol values (5-10 mg subcutaneous, 10-20 consecutive days, early evening) trace to ER lines 405, 409, 413; time-to-effect values to ER line 458; benefits/risks headings to ER lines 157-237 and 263-321; contraindications to ER lines 353, 367-375; interactions to ER lines 343-363; all 11 monitoring rows and the cadence to ER lines 484-498; qualitative items to ER lines 502-509. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Theoretical cancer promotion” retained verbatim; “No dose-finding trial has been published” retained; “on mechanistic reasoning, not a tested finding” retained; “not evidence the longevity mechanism is operating” retained. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy, conception and lactation remain in Contraindications, not Key Interactions; transplant immunosuppression remains absolute; imetelstat remains an absolute contraindication. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications map to the ER’s “Populations who should avoid this intervention” list plus the two ER interaction bullets the ER itself designates “Absolute contraindication”; no Benefit- or Risk-Modifying Factor was promoted into a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, or expert names appear. Named agents (imetelstat, TA-65, Thymalin, Vilon, Cortexin, warfarin, apixaban, rivaroxaban, clopidogrel, tacrolimus, ciclosporin, mycophenolate) all appear in ER lines 343-363 for the same facts. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No institution, author, or organisation is named anywhere in the QRS beyond what the ER Conclusion states (“the Russian institute that patented it”). |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | The ER’s skeptical, evidence-first register is carried through: single-source human evidence, supply-chain hazard, and the unresolved cancer question all surface at the same weight the ER gives them. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Concrete thresholds and targets throughout (melatonin peak > 10 pg/mL, HOMA-IR < 1.0, PSA velocity < 0.35 ng/mL per year) give the reader actionable levers rather than a verdict. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Statements are descriptive of what protocols and source trials did, not instructions issued to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives are used; the footer disclaimer is the template’s unchanged text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Cadence text is written in the passive descriptive (“Full panel drawn and reviewed before the first injection”), not as a recommendation. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns occur anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Remaining technical terms are unavoidable identifiers (gene, drug, and biomarker names) carried verbatim from the ER; the At-A-Glance and time-to-effect prose are plain. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are single clauses with mechanistic rationale, effect sizes, and attributions stripped relative to the ER. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text scan: no “you”, “your”, or direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | The sheet assumes willingness to run an 11-marker panel, obtain lot-specific quality documentation, and self-monitor across a course. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Daily subcutaneous injection over 10-20 days, nightly sleep tracking, and twice-daily glucose self-monitoring are presented without hedging about burden. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content density, functional (not conventional) biomarker targets, and the assumption of baseline cancer screening all place it outside general-population material. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The sheet foregrounds exactly the discriminators this audience needs: product-quality risk graded High, the telomerase/ALT cancer question, and the fact that the endpoints motivating use are unobservable within a course. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Anti-aging” does not occur; the sheet uses “longevity mechanism” and the title “Epitalon for Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “Subcutaneous”, “injection”, “injection-site reactions”, “hypersensitivity”, “daytime somnolence” are used throughout; no colloquial substitutes appear. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fourteen fixed strings verified byte-identical to the template at QRS lines 446, 492, 542, 578, 606, 648, 680, 684-686, and the four tier labels in the Benefits and Risks cards. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variable names are present; the four repeatable names (marker_#name/target/why, qualitative_item#) are expanded to 11 marker rows and 8 qualitative rows. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A structural diff against the template shows changes confined to variable regions; the three website= spans, the full stylesheet, the override link, and the footer disclaimer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section feeding the QRS is empty; every benefit tier, risk tier, gate, and monitoring row has ER content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Contraindication and interaction items carry the ER bullet labels verbatim (“Sedatives and hypnotics”, “Melatonin-modulating prescription drugs”, “Other peptide bioregulators”); the 11 Monitoring row labels match the ER table’s Biomarker column verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Benefit and risk items reuse the ER’s own subsection headings; monitoring markers reuse the ER’s biomarker names. The Protocol and Time-to-Effect cell labels are dimension headers required by the template, since the corresponding ER content is prose within single bullets rather than one-to-one labelled items. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-text scan for emoji code points returns nothing; the ER’s ⚠️ Conflicted markers on two headings were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than transcribed: benefit and risk tiers collapse to one semicolon-joined line each, gate items are stripped of all trailing rationale, and the ER’s four-column monitoring table is reduced to three columns with the Context/Notes column dropped entirely. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | QRS lines 2-14: the comment opens on line 2, immediately after <!doctype html> on line 1, and precedes the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13, preceded by the permitted descriptive text on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | The block sits entirely inside an HTML comment and no metadata value is repeated in the header, footer, or any span. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:04" is quoted, correctly, because it contains a colon; all other values are bare and untrimmed of nothing. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: epitalon_2026-0805-0849_Opus_ER.md, matching the ER’s own filename frontmatter value. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0805-1430, correctly formatted. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no trailing qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: epitalon_2026-0805-0849_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys including git_user: evipedia-3 and git_issue: 4798; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | QRS line 22: Epitalon for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand correctly encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | QRS line 417: Epitalon for Health & Longevity. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | QRS line 421: 08/05/2026, correctly derived from qrs_creation_date: 2026-0805-1430. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | QRS line 425: Opus 5, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header contains only the title and the template’s subline; the ER’s “Also known as” line (Epithalon, Epithalone, AEDG Peptide, Ala-Glu-Asp-Gly) was correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Every clause maps to the ER Conclusion (lines 533-535): the pineal-mimic description, the cell-culture telomere result, the cancer-step caveat, the modest animal survival gains, the single-source human evidence, unapproved status, unverified supply, and the sport prohibition. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “restarting a step most cancers take” ← ER line 535; “the Russian institute that patented it” ← ER line 533; “barred from competitive sport” ← ER lines 271, 535; “sold unverified” ← ER line 535. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms. “Pineal gland” is rendered as “the small brain structure that sets the sleep-wake cycle” and “telomeres” as “the protective caps on chromosomes”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No study name, year, sample size, or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | Effects are described qualitatively (“modest survival gains”); no numbers appear at all. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items trace to ER lines 351, 353, and 367-375, within that section. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All nine bullets of the ER’s “Populations who should avoid this intervention” list are present, plus the imetelstat bullet the ER itself designates an “Absolute contraindication” at line 353. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | QRS lines 581-601: ten discrete <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing clauses were all stripped: “— no reproductive toxicity data of any kind exist”, “where developmental effects on the pineal-pituitary axis are entirely uncharacterized”, “for whom S0 status makes use a sanctionable violation irrespective of intent”, “where repeated daily subcutaneous injection carries meaningful bleeding risk”. No dash-trailing content remains. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “within the previous 5 years” preserved; “in a flare” preserved; “on maintenance immunosuppression” preserved; the thresholds “below 50 × 10⁹/L” and “above 3.0” preserved verbatim; the biologic examples (infliximab, adalimumab, rituximab) and the TP53 / TERT promoter qualifiers preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication bullets contain no ranking notation inside parentheses; thresholds are expressed in words (“below”, “above”). |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Ten stop_items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items map one-to-one onto ER bullets at lines 343-363. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Ten of the ER’s eleven interaction bullets appear; the imetelstat bullet is correctly excluded because it is carried in Contraindications, and the immunosuppressant bullet is correctly narrowed to its caution half (“in autoimmune disease”) since its absolute half sits in Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | QRS lines 609-638: ten discrete <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER bullet’s “Caution./Monitor.” verdict, consequence sentence, and “Mitigation:” clause was stripped; the em-dash separating label from drug list was converted to a parenthetical, leaving no trailing dash content. The Vilon breast-cancer elaboration at ER line 363 was correctly dropped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every bullet retains its named examples: warfarin/apixaban/rivaroxaban/clopidogrel, tacrolimus/ciclosporin/mycophenolate, TA-65/cycloastragenol/Astragalus membranaceus, Thymalin/Vilon/Cortexin, and the full OTC and supplement lists. Where the ER nested a second parenthetical layer (e.g., benzodiazepines → diazepam, temazepam), the outer class names are kept and the inner examples trimmed for the one-page budget. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets contain no ranking notation inside parentheses. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Ten caution_items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to the ER Therapeutic Protocol section at lines 401-419, with the “no taper” detail from the ER’s Discontinuation & Cycling section at line 432. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose and route, course structure and cycling, and time of day are the three implementation decisions the ER Protocol section actually specifies; the remaining bullets (half-life, split dosing, pharmacogenetics, sex, age) are explicitly non-actionable in the ER. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct actionable aspects exist in the ER and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine variables carry ER-derived content: “5-10 mg subcutaneous” and the 2 mg variant from line 405; “10-20 consecutive days” with 3-4 month intervals from lines 405 and 436; “Early evening” with the 2-3 hour adjustment from line 409; “No dose-finding trial has been published” from line 401. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | The ER’s Time to effect bullet (line 458) names exactly three timescales — sleep-related at 3-7 days, metabolic over a course, and telomere / cardiovascular aging / mortality at 3-15 years — and all three are carried. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered telomere-and-mortality first (tied to the ER’s only High-tier benefit), then metabolic (Low tier), then sleep (Speculative tier). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine variables carry ER content; the subs paraphrase ER line 458 closely, including “not observable on any timescale a person can perceive” and “a short-term circadian or subjective effect, not evidence the longevity mechanism is operating”. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information at line 458, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All fourteen benefit items correspond to the fourteen subsection headings under ER Expected Benefits at lines 155-237. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present and populated: 1 High, 3 Medium, 6 Low, 4 Speculative — matching the ER’s tier counts exactly. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Only the ER’s headings are carried; every Magnitude paragraph, effect size (11-31% lifespan, 3.7-fold, 6.0-fold, 18%/41%/55%), and institutional attribution was dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER heading “Reduced Chromosomal Damage (Antimutagenic Effect)” is carried as “reduced chromosomal damage” with the parenthetical correctly stripped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All ten risk items correspond to the ten subsection headings under ER Potential Risks & Side Effects at lines 261-321. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present and populated: 2 High, 2 Medium, 3 Low, 3 Speculative — matching the ER’s tier counts exactly. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Only the ER’s headings are carried; the Belgian laboratory findings, the 5% purity figure, the S0 sanction lengths, and all Magnitude text were dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER’s in-text glosses (erythema, induration, urticaria, anaphylaxis definitions) and the ⚠️ Conflicted marker on the cancer-promotion heading are all absent from the QRS items. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All rows derive from the ER Monitoring Protocol & Defining Success table at lines 482-494. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 11 ER biomarkers are present in ER order with targets and rationale carried verbatim: nocturnal salivary melatonin, leukocyte telomere length, hs-CRP, fasting glucose, fasting insulin and HOMA-IR, HbA1c, complete blood count with differential, comprehensive metabolic panel, IGF-1, PSA (men over 45), morning cortisol. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | QRS lines 854-861 condense ER lines 496-498: baseline before first injection with cancer screening, metabolic subset plus hs-CRP at ~3 weeks, full panel at 6 months then every 6-12 months, telomere length every 12-24 months, and twice-daily glucose self-monitoring on insulin or a sulfonylurea. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All eight items derive from the “Qualitative markers” list in the ER Monitoring Protocol & Defining Success section at lines 502-509. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All eight ER qualitative markers are present in ER order: sleep onset latency and awakenings, sleep depth and morning refreshment, daytime alertness and sedation, cognitive clarity and working memory, energy stability, injection-site appearance at 24 hours, mood and stress reactivity, and any new symptom beyond 72 hours. |
Issues 05/08/2026 14:37
Pass rate 100.00%. No issues found.